Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
11.59
-0.11 (-0.94%)
At close: Jul 19, 2024, 4:30 PM
11.97
+0.38 (3.28%)
Pre-market: Jul 22, 2024, 7:43 AM EDT
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock have an average target of 19, with a low estimate of 5.00 and a high estimate of 26. The average target predicts an increase of 63.93% from the current stock price of 11.59.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for YMAB stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 3 | 4 | 5 |
| Buy | 1 | 2 | 2 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 0 | 0 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +98.45% | Jul 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +81.19% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $21 → $22 | Strong Buy | Maintains | $21 → $22 | +89.82% | May 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains n/a | Strong Buy | Maintains | n/a | n/a | Mar 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +124.33% | Mar 4, 2024 |
Financial Forecast
Revenue This Year
98.63M
from 84.82M
Increased by 16.29%
Revenue Next Year
119.58M
from 98.63M
Increased by 21.24%
EPS This Year
-0.48
from -0.49
EPS Next Year
-0.45
from -0.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.1M | 139.7M | 137.8M | 153.2M | 260.3M |
| Avg | 98.6M | 119.6M | 127.8M | 143.5M | 252.9M |
| Low | 90.8M | 102.6M | 118.3M | 132.7M | 242.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.9% | 41.6% | 15.2% | 19.9% | 81.4% |
| Avg | 16.3% | 21.2% | 6.8% | 12.3% | 76.2% |
| Low | 7.0% | 4.1% | -1.0% | 3.9% | 69.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.37 | -0.16 | -1.12 |
| Avg | -0.48 | -0.45 | -1.14 |
| Low | -0.70 | -0.83 | -1.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.